Preparing for Ocular Therapeutix's Upcoming Results Announcement
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a dedicated biopharmaceutical company, is gearing up to announce its third-quarter results. This milestone will be marked by a conference call and webcast scheduled for Thursday, November 14 at 8:00 AM ET. The session aims to inform stakeholders about the company's recent business progress and financial performance.
Conference Call and Webcast Details
The conference call is an excellent opportunity for investors and analysts to gain insights directly from the Ocular Therapeutix leadership team. Participants can join the call by dialing 1 (877) 407-9039 in the U.S. or 1 (201) 689-8470 for international access. The company encourages everyone interested to also tune into the webcast, where the presentation materials will be shared and discussed.
Webcast Access
The live webcast will be accessible on the official Ocular Therapeutix website, specifically in the Events and Presentations section within the Investor Relations page. For those unable to join live, a replay will be available for at least 30 days following the event.
About Ocular Therapeutix, Inc.
Ocular Therapeutix is deeply committed to enhancing visual health by developing innovative therapies designed to treat retinal diseases and various ocular conditions. One of its notable product candidates is AXPAXLI™ (also known as OTX-TKI), a promising solution currently undergoing Phase 3 clinical trials for wet age-related macular degeneration, a leading cause of vision loss among older adults.
Pioneering Technology and Pipeline
The company's pioneering ELUTYX™ proprietary technology forms the backbone of its product offerings. DEXTENZA®, Ocular's FDA-approved corticosteroid for post-operative ocular inflammation and pain, exemplifies the application of this cutting-edge formulation. Furthermore, Ocular is progressing with PAXTRAVA™, an intracameral implant for treating open-angle glaucoma or ocular hypertension, which has successfully completed its Phase 2 trials.
Innovative Therapeutic Approaches
In striving for better outcomes in ocular health, Ocular Therapeutix is continually focused on developing differentiated therapies that promise greater efficacy and comfort for patients. The ongoing clinical trials and promising pipeline signify Ocular's commitment to transforming patient care in vision therapy. The innovation of AXPAXLI stands to create a significant impact in managing retinal diseases, potentially offering new hope for patients.
Staying Connected
Ocular Therapeutix maintains a robust communication channel with investors and the public through its official website and social media platforms, including LinkedIn and X. Interested parties are encouraged to follow these channels for the latest updates on the company and its products.
Contact Information for Investors & Media
For inquiries related to investor relations, Bill Slattery, Vice President of Investor Relations, is the primary contact. He can be reached via email for any collaboration or questions pertaining to the company’s financial health and projections.
Frequently Asked Questions
1. What is the date for Ocular Therapeutix's Q3 results call?
The conference call is scheduled for November 14 at 8:00 AM ET.
2. How can I access the webcast for the event?
The webcast will be available on Ocular Therapeutix's Investor Relations page on their official website.
3. What product is currently undergoing Phase 3 clinical trials?
AXPAXLI™, targeting wet age-related macular degeneration, is in Phase 3 trials.
4. What is DEXTENZA®, and what is its purpose?
DEXTENZA® is an FDA-approved product for the treatment of ocular inflammation and pain following surgical procedures.
5. Where can I find more information about Ocular Therapeutix?
More information can be found on Ocular Therapeutix's official website and their social media profiles on LinkedIn and X.
